Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-8 of 8 for your search:
Drug:
ticilimumab
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase 3 Trial of CP-675,206 Versus Either Dacarbazine or Temozolomide in Patients Without Prior Therapy
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A3671009
, NCT00257205
2.
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A3671004
, NCT00075192
3.
CP-675,206 In Patients With Advanced Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A3671002
, NCT00086489
4.
Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A3671015
, NCT00312975
5.
Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A3671014
, NCT00313794
6.
Phase II Study of Ticilimumab (CP-675,206) in Patients With Stage IIIC or IV Melanoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Closed
Age:
Not specified
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
UCLA-0606093-01
, 06-06-093-01, PFIZER-UCLA-0606093-01, NCT00471887
7.
Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A3671011
, NCT00431275
8.
Study of the Effects of Immune-Modulating Therapies on Tissue Expression of Indoleamine 2, 3 dioxygenase in Patients With Untreated Acute or Chronic Hepatitis C, Metastatic Melanoma, or Crohn Disease
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis
Status:
Completed
Age:
No age specified
Sponsor:
NCI
Protocol IDs:
VU-VICC-MEL-0651
, VICC-MEL-0651, VU-VICC-060614
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute